Cagrilintide
- CAS No.
- 1415456-99-3
- Chemical Name:
- Cagrilintide
- Synonyms
- Caglitide;Cargliptin;Cagrilintide;Cagrilintide acetate
- CBNumber:
- CB712152538
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
form | Solid |
---|---|
color | White to off-white |
FDA UNII | AO43BIF1U8 |
Cagrilintide Chemical Properties,Uses,Production
Description
Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. This drug is an investigational therapy that reduced body weight in a phase 2 trial when administered as monotherapy in participants without diabetes and with a BMI of at least 30 kg/m2 or at least 27 kg/m2 with hypertension or dyslipidaemia[1-2].
Mechanism of action
Cagrilintide, a non-selective agonist, is designed for weekly subcutaneous injection at low pH. It is based on the h-amylin backbone, drawing inspiration from calcitonin, and exhibits a prolonged action profile, likely attributed to reversible albumin binding similar to semaglutide. This amylin analog is currently under development in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in individuals with overweight and obesity. Amylin, co-secreted with insulin from pancreatic beta cells, exerts its satiating effect through both the homoeostatic and hedonic brain regions. On the other hand, semaglutide, a GLP-1 receptor agonist, reduces appetite by acting on GLP-1 receptors in the hypothalamus, increases insulin production, and decreases glucagon secretion, thus delaying gastric emptying. These distinct yet interconnected mechanisms of action of an amylin analog and a GLP-1 receptor agonist appear to synergistically reduce appetite[3-4].
Side effects
The most frequent adverse events were gastrointestinal disorders (e.g., nausea, constipation, and diarrhoea) and administration-site reactions. More participants receiving cagrilintide 0·3-4·5 mg had gastrointestinal adverse events compared with placebo (41%-63% vs 32%), primarily nausea (20%-47% vs 18%)[5].
References
[1] Antonella M D’Ascanio, William H Frishman, & Jamie A Mullally. “Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.” Cardiology in Review (2024): 83–90.
[2] Juan P Frias. “Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.” Lancet 402 10403 (2023): 720–730.
[3] Antonella M D’Ascanio, William H Frishman, Jamie A Mullally. “Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.” Cardiology in Review (2024): 83–90.
[4] Thomas Kruse*. “Development of Cagrilintide, a Long-Acting Amylin Analogue.” Journal of Medicinal Chemistry 64 15 (2021): 11183–11194.
[5] David C W Lau. “Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.” Lancet (2021): 2160–2172.
Cagrilintide Preparation Products And Raw materials
Raw materials
Preparation Products
Cagrilintide Suppliers
Supplier | Tel | Country | ProdList | Advantage | |
---|---|---|---|---|---|
Sea Biological Co.,LTD | +86-13865152372 +86-13865152372 | tim@sea-biol.com | China | 71 | 58 |
Sichuan Tai Hui Biotechnology Co., Ltd | +86-18224031330 +86-18081096520 | 404435307@qq.com | China | 26 | 58 |
Hebei Lingding Biotechnology Co., Ltd. | +86-18031140164 +86-19933155420 | erin@hbldbiotech.com | China | 5 | 58 |
Dorne Chemical Technology co. LTD | +86-86-13583358881 +8618560316533 | Ethan@dornechem.com | China | 3145 | 58 |
Hebei Anlijie Biotechnology Co., Ltd | +8619031013551 | ably@aljbio.com | China | 145 | 58 |
CONTIDE BIOTECH CO.,LTD | +852-53358525 | xena@healthtide-api.com | China | 568 | 58 |
Strong peptide cross-border e-commerce Co. LTD | +undefined13930052870 | qt01@qiangtaipharm.com | China | 84 | 58 |
Qingdao Xinli Technology Development Co., Ltd. | +8616632313095 | xinlikeji01@qdxlchem.com | China | 135 | 58 |
Shaanxi Cuikang Pharmaceutical Technology Co., Ltd | +86-19164747840 +86-13119157289 | 13119157289@163.com | China | 2972 | 58 |
Shanghai Affida new material science and technology center | +undefined15081010295 | admin@oudaxin.com | China | 114 | 58 |
View Lastest Price from Cagrilintide manufacturers
Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
---|---|---|---|---|---|---|---|---|
2024-08-24 | Cagrilintide
1415456-99-3
|
US $1.00 / g | 1g | 99% | 100kg | Dorne Chemical Technology co. LTD | ||
2024-08-24 | cagrilintide
1415456-99-3
|
US $45.00 / Box | 1Box | 99.99% | 10000000000 | zhuzhou dingcheng meihei comestic co.,ltd | ||
2024-08-22 | Cagrilintide
1415456-99-3
|
US $70.00-65.00 / box | 1box | 99.9% | 2000box | Strong peptide cross-border e-commerce Co. LTD |
- Cagrilintide
1415456-99-3
- US $1.00 / g
- 99%
- Dorne Chemical Technology co. LTD
- cagrilintide
1415456-99-3
- US $45.00 / Box
- 99.99%
- zhuzhou dingcheng meihei comestic co.,ltd
- Cagrilintide
1415456-99-3
- US $70.00-65.00 / box
- 99.9%
- Strong peptide cross-border e-commerce Co. LTD